Maximus, Inc. (MMS) Downgraded to “Hold” at Zacks Investment Research

Maximus, Inc. (NYSE:MMS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “MAXIMUS, Inc. is an extremely dynamic and complex organization that offers government and industry a range of unique services, products, and solutions. The diverse services and products that MAXIMUS offers may be categorized into three groups: Government Program Management and Operations, Consulting, and Systems. Government Program Management and Operations focuses on having a measurable impact on the lives of the citizens we help government serve. The insights of MAXIMUS Consulting, and the technological innovations advanced through Systems, help government gain program efficiencies and pursue improvements that in turn benefit citizens. “

Several other equities analysts have also commented on the company. BidaskClub lowered Maximus from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 6th. Canaccord Genuity lowered Maximus from a “buy” rating to a “hold” rating and set a $62.00 price objective on the stock. in a research report on Tuesday, July 4th. Robert W. Baird reiterated a “hold” rating and set a $64.00 price objective on shares of Maximus in a research report on Friday, September 1st. Finally, Maxim Group set a $66.00 price objective on Maximus and gave the company a “hold” rating in a research report on Thursday, August 3rd. One research analyst has rated the stock with a sell rating and nine have issued a hold rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $63.14.

Maximus (MMS) opened at 65.35 on Tuesday. Maximus has a 52-week low of $43.69 and a 52-week high of $65.87. The firm has a 50-day moving average price of $62.58 and a 200-day moving average price of $61.86. The company has a market cap of $4.24 billion, a PE ratio of 20.95 and a beta of 1.36.

Maximus (NYSE:MMS) last released its quarterly earnings results on Thursday, August 3rd. The health services provider reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.76 by $0.03. Maximus had a return on equity of 25.08% and a net margin of 8.43%. The firm had revenue of $600.40 million for the quarter, compared to analysts’ expectations of $614.12 million. During the same quarter last year, the firm posted $0.79 EPS. The company’s revenue was down 2.7% compared to the same quarter last year. On average, analysts forecast that Maximus will post $3.13 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This article was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://ledgergazette.com/2017/10/10/maximus-inc-mms-downgraded-to-hold-at-zacks-investment-research.html.

In related news, CEO Richard A. Montoni sold 29,203 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $60.38, for a total transaction of $1,763,277.14. Following the transaction, the chief executive officer now directly owns 549,215 shares in the company, valued at approximately $33,161,601.70. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, President Bruce Caswell sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 12th. The stock was sold at an average price of $62.21, for a total value of $497,680.00. Following the transaction, the president now owns 35,904 shares in the company, valued at $2,233,587.84. The disclosure for this sale can be found here. Insiders have sold a total of 160,403 shares of company stock worth $9,912,181 over the last quarter. Corporate insiders own 3.10% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of MMS. Acrospire Investment Management LLC grew its position in Maximus by 17.6% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,000 shares of the health services provider’s stock worth $125,000 after acquiring an additional 300 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Maximus by 10.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,367 shares of the health services provider’s stock worth $148,000 after acquiring an additional 220 shares during the last quarter. First Bank & Trust grew its position in Maximus by 4.2% during the 2nd quarter. First Bank & Trust now owns 2,507 shares of the health services provider’s stock worth $157,000 after acquiring an additional 101 shares during the last quarter. Intl Fcstone Inc. bought a new position in Maximus during the 2nd quarter worth approximately $201,000. Finally, GW Henssler & Associates Ltd. bought a new position in Maximus during the 2nd quarter worth approximately $205,000. Institutional investors and hedge funds own 97.23% of the company’s stock.

About Maximus

MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides B

According to Zacks, “MAXIMUS, Inc. is an extremely dynamic and complex organization that offers government and industry a range of unique services, products, and solutions. The diverse services and products that MAXIMUS offers may be categorized into three groups: Government Program Management and Operations, Consulting, and Systems. Government Program Management and Operations focuses on having a measurable impact on the lives of the citizens we help government serve. The insights of MAXIMUS Consulting, and the technological innovations advanced through Systems, help government gain program efficiencies and pursue improvements that in turn benefit citizens. “

Several other equities analysts have also commented on the company. BidaskClub lowered Maximus from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 6th. Canaccord Genuity lowered Maximus from a “buy” rating to a “hold” rating and set a $62.00 price objective on the stock. in a research report on Tuesday, July 4th. Robert W. Baird reiterated a “hold” rating and set a $64.00 price objective on shares of Maximus in a research report on Friday, September 1st. Finally, Maxim Group set a $66.00 price objective on Maximus and gave the company a “hold” rating in a research report on Thursday, August 3rd. One research analyst has rated the stock with a sell rating and nine have issued a hold rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $63.14.

Maximus (MMS) opened at 65.35 on Tuesday. Maximus has a 52-week low of $43.69 and a 52-week high of $65.87. The firm has a 50-day moving average price of $62.58 and a 200-day moving average price of $61.86. The company has a market cap of $4.24 billion, a PE ratio of 20.95 and a beta of 1.36.

Maximus (NYSE:MMS) last released its quarterly earnings results on Thursday, August 3rd. The health services provider reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.76 by $0.03. Maximus had a return on equity of 25.08% and a net margin of 8.43%. The firm had revenue of $600.40 million for the quarter, compared to analysts’ expectations of $614.12 million. During the same quarter last year, the firm posted $0.79 EPS. The company’s revenue was down 2.7% compared to the same quarter last year. On average, analysts forecast that Maximus will post $3.13 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This article was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://ledgergazette.com/2017/10/10/maximus-inc-mms-downgraded-to-hold-at-zacks-investment-research.html.

In related news, CEO Richard A. Montoni sold 29,203 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $60.38, for a total transaction of $1,763,277.14. Following the transaction, the chief executive officer now directly owns 549,215 shares in the company, valued at approximately $33,161,601.70. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, President Bruce Caswell sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 12th. The stock was sold at an average price of $62.21, for a total value of $497,680.00. Following the transaction, the president now owns 35,904 shares in the company, valued at $2,233,587.84. The disclosure for this sale can be found here. Insiders have sold a total of 160,403 shares of company stock worth $9,912,181 over the last quarter. Corporate insiders own 3.10% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of MMS. Acrospire Investment Management LLC grew its position in Maximus by 17.6% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,000 shares of the health services provider’s stock worth $125,000 after acquiring an additional 300 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Maximus by 10.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,367 shares of the health services provider’s stock worth $148,000 after acquiring an additional 220 shares during the last quarter. First Bank & Trust grew its position in Maximus by 4.2% during the 2nd quarter. First Bank & Trust now owns 2,507 shares of the health services provider’s stock worth $157,000 after acquiring an additional 101 shares during the last quarter. Intl Fcstone Inc. bought a new position in Maximus during the 2nd quarter worth approximately $201,000. Finally, GW Henssler & Associates Ltd. bought a new position in Maximus during the 2nd quarter worth approximately $205,000. Institutional investors and hedge funds own 97.23% of the company’s stock.

About Maximus

MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.

Analyst Recommendations for Maximus (NYSE:MMS)

Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply